Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant and Ondansetron for PONV in Thyroid Carcinoma
NCT06697782Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of aprepitant in postoperative nausea and vomiting (PONV), sponsored by The First Affiliated Hospital of Zhengzhou University. Started Jul 2024; status: completed.
02
Drugs
aprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT06697782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06697782.